Skip to main content

8 Result(s)

within D Kirn Remove this filter Biomedicine Remove this filter Human Genetics Remove this filter

and

  1. Article

    Gene therapy progress and prospects cancer: oncolytic viruses

    The past 2 years have seen several major advances in oncolytic virotherapy. Studies on the interaction between viruses, immune responses and tumor microenvironment have provided important insight, while clinic...

    T-C Liu, D Kirn in Gene Therapy (2008)

    Download PDF (166 KB) View Article

  2. No Access

    Article

    Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus

    Replication-selective oncolytic adenoviruses hold promise, but novel mechanisms must be identified to maximize intratumoral virus persistence, spread and therapeutic transgene-carrying capacity while maintaini...

    T-C Liu, Y Wang, G Hallden, G Brooks, J Francis, N R Lemoine, D Kirn in Gene Therapy (2005)

  3. No Access

    Chapter and Conference Paper

    Oncolytic Virotherapy as a Novel Treatment Platform for Cancer

    New cancer treatments are needed. These agents must have novel mechanisms of action and thereby lack cross-resistance with currently available treatments. Viruses have evolved to infect, replicate in, and kill...

    D. Kirn in Human Gene Therapy: Current Opportunities and Future Trends (2003)

  4. No Access

    Article

    Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial

    Both replication-incompetent and replication-selective adenoviruses are being developed for the treatment of cancer and other diseases. Concerns have been raised about the safety of intra-vascular adenovirus a...

    T Reid, E Galanis, J Abbruzzese, D Sze, J Andrews, L Romel, M Hatfield… in Gene Therapy (2001)

  5. No Access

    Article

    Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity

    Although genetically engineered adenoviruses hold promise for the treatment of cancer, clinical trial reports have utilized intratumoral injection to date. To determine the feasibility of intravenous delivery ...

    J Nemunaitis, C Cunningham, A Buchanan, A Blackburn, G Edelman, P Maples… in Gene Therapy (2001)

  6. No Access

    Article

    Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial

    Novel therapies are needed for locally advanced pancreatic carcinoma. ONYX-015 (dl1520) is an E1B-55 kDa region-deleted adenovirus that selectively replicates in and lyses tumor cells with abnormalities in p53...

    S Mulvihill, R Warren, A Venook, A Adler, B Randlev, C Heise, D Kirn in Gene Therapy (2001)

  7. No Access

    Article

    Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?

    Replication-selective microbial agents hold promise as a novel cancer treatment platform. dl1520 (Onyx-015), an E1B-55 kD gene-deleted adenovirus, was the first such genetically engineered agent to be tested i...

    D Kirn in Gene Therapy (2001)

  8. No Access

    Article

    Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status

    Intraperitoneal (i.p.) recurrence of cisplatin-refractory and p53 mutant ovarian cancer is a major clinical problem, despite surgery and chemotherapy. dl1520 (ONYX-015) is an E1B–55 kDa gene-deleted adenovirus...

    C Heise, I Ganly, Y T Kim, A Sampson-Johannes, R Brown, D Kirn in Gene Therapy (2000)